eBenefits Advantage

A free online portal to manage your group health plan and streamline your insurance process.

Learn more here »

Member Discount Program

Take advantage of premiums and discounts.

Click here to save »

Search the Member Directory By:

Paid Advertisement

Advertise with the Chamber

UCSC Verizon Wireless Verizon The Children's Scholarship Fund Brownstone PR

1020 First Ave., P.O. Box 61501
King of Prussia, PA 19406-0901

Get Directions

CSL Behring

Pharmaceutical & Medicine Manufacturing view similar »

Contact Information
Business Information
  • Established in 1991
  • Located in Montgomery County
  • 300 Full-Time Employees
  • Over 20 Million in Annual Revenue

Business Description:

Biopharmaceutical/Therapeutic Proteins

Most Recent Bulletin Board Posts

view more»
CSL Behring Recognized for Rare Disease R&D

Posted to Announcement by Mr. Christopher Florentz of CSL Behring at 9:04 AM

CSL Behring, a global biotherapeutics company specializing in plasma-derived and recombinant therapies and a subsidiary of CSL Limited (ASX:CSL), is a recipient of the National Organization for Rare Disorders (NORD) 2011 Corporate Award. The award was presented at the NORD Partners in Progress Celebration 2011 for “new treatments brought to market for patients with rare diseases.”

CSL Behring’s new treatment, factor XIII concentrate (human), is approved for the routine prophylactic treatment of congenital factor XIII deficiency, an extremely rare and potentially life-threatening bleeding disorder. Congenital factor XIII deficiency is estimated to affect one person in two million, with an incidence in the U.S. of approximately 150 people.

Related Link: Click to View

New President at CSL Behring Announced

Posted to Announcement by Mr. Christopher Florentz of CSL Behring at 9:56 AM

CSL Limited (ASX:CSL) Australia’s leading biopharmaceutical company, has announced a change to its senior executive group. Peter Turner, President of CSL Behring in King of Prussia, PA, will hand over his responsibilities as President to Paul Perreault effective July 1, 2011.

Paul Perreault is currently a member of the CSL Behring leadership team holding the position Executive Vice President, Commercial Operations. His career spans 30 years in the pharmaceutical industry in sales, marketing, business development and operational roles with both a US and international focus.

The announcement can be viewed in its entirety at http://www.csl.com.au/s1/cs/auhq/1182280826145/news/1255926123898/prdetail.htm

Related Link: Click to View

Related File: Click to View

CSL Behring's Key Issues Dialogue Series Examines Challenges in Treating Patients with Hereditary Angioedema

Posted to Announcement by Mr. Christopher Florentz of CSL Behring at 11:50 AM

CSL Behring announces publication of the latest in its ongoing Key Issues Dialogue Series – "Hereditary Angioedema (HAE) in the US." The Dialogue brought together thought leaders from the medical science and patient advocacy communities to examine critical issues affecting people with HAE.


The participants included prominent physician-researchers who agreed that a lack of understanding about HAE is commonplace in the medical community, often resulting in unnecessary surgery and inappropriate treatment. The complete Dialogue is available for download: http://www.cslbehring-us.com/about-CSL-Behring/dialogue-series.htm


CSL Behring is a leader in the plasma protein therapeutics industry. The company manufactures and markets a range of plasma-derived and recombinant therapies worldwide for the treatment of rare and serious diseases and for use in cardiac surgery, organ transplantation and burn treatment, and to prevent hemolytic diseases in the newborn.

Related Link: Click to View